NASDAQ:INCR InterCure (INCR) Stock Price, News & Analysis → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Free INCR Stock Alerts $2.58 +0.05 (+1.98%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$2.52▼$2.6250-Day Range$1.59▼$2.7252-Week Range$0.99▼$2.92Volume27,331 shsAverage Volume66,809 shsMarket Capitalization$117.57 millionP/E Ratio19.85Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get InterCure alerts: Email Address Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About InterCure Stock (NASDAQ:INCR)InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Read More INCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INCR Stock News HeadlinesApril 14, 2024 | americanbankingnews.comInterCure Ltd. (NASDAQ:INCR) Short Interest Down 14.6% in MarchApril 1, 2024 | msn.comThis Israeli Cannabis Operator Anticipates $95.4M In Revenue Despite Gaza ConflictApril 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. March 22, 2024 | businesswire.comInterCure Congratulates Germany on Cannabis Reform, Expanding its Global FootprintFebruary 23, 2024 | businesswire.comPESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis LandscapeFebruary 13, 2024 | finance.yahoo.comInterCure Provides an Update Regarding Nir Oz FacilityFebruary 13, 2024 | globenewswire.comInterCure Provides an Update Regarding Nir Oz FacilityJanuary 31, 2024 | msn.comInterCure to buy Isreal-based Leon cannabis pharmacy chainApril 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. January 18, 2024 | investing.comIntrakat Technikon Kai Energeiakon Ergon AE (INCr)January 10, 2024 | msn.comWKEY, INCR and ZJYL are among pre market gainersJanuary 9, 2024 | benzinga.comIntercure Stock (NASDAQ:INCR) Dividends: History, Yield and DatesJanuary 6, 2024 | investing.comINCR_t3 Historical DataNovember 9, 2023 | morningstar.comIntercure Ltd INCROctober 17, 2023 | msn.comInterCure says one of its sites designated as closed military area by Israeli authoritiesSeptember 1, 2023 | benzinga.comCanndoc Reports Record Revenue Amid Cannabis Market TurmoilAugust 22, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd up on Monday (INCR-U)August 19, 2023 | theglobeandmail.comul: Bottom 25 Performing Stocks Year-to-Date on TSX (INCR-U)August 3, 2023 | msn.comInterCure: Leader In Israel's Growing Medical Cannabis MarketJuly 23, 2023 | theglobeandmail.comIntercure: Top 10 Undervalued Micro Cap Stocks on TSX (INCR-U)July 10, 2023 | financialpost.comInterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASEMay 16, 2023 | finanznachrichten.deInterCure Ltd.: InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOYMay 16, 2023 | msn.comInterCure Stock Trading Lower On Q1 Revenue Growth Of 22%, Here Are The DetailsMay 15, 2023 | benzinga.comInterCure Announces Record Breaking First Quarter Revenues with 22% growth YOYApril 27, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd down on Monday (INCR-U)April 26, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd flat on Monday (INCR-U)April 25, 2023 | finance.yahoo.comInterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its SubsidiarySee More Headlines Receive INCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InterCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INCR CUSIPN/A CIK1857030 Webwww.intercure.co Phone972774605012FaxN/AEmployees370Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio19.85 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$115.83 million Price / Sales1.02 Cash Flow$0.40 per share Price / Cash Flow6.42 Book Value$3.64 per share Price / Book0.71Miscellaneous Outstanding Shares45,570,000Free FloatN/AMarket Cap$117.57 million OptionableOptionable Beta1.72 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Alexander Rabinovich (Age 53)CEO & Director Comp: $500kMr. Amos Cohen (Age 45)Chief Financial Officer Comp: $848kEinat ZehaviVice President of SalesMr. Omri BatzirCorporate ControllerKey CompetitorsPDS BiotechnologyNASDAQ:PDSBRelmada TherapeuticsNASDAQ:RLMDCoya TherapeuticsNASDAQ:COYANuvectis PharmaNASDAQ:NVCTAdageneNASDAQ:ADAGView All CompetitorsInstitutional OwnershipSimplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions INCR Stock Analysis - Frequently Asked Questions How have INCR shares performed in 2024? InterCure's stock was trading at $1.2898 at the beginning of 2024. Since then, INCR stock has increased by 100.0% and is now trading at $2.58. View the best growth stocks for 2024 here. Are investors shorting InterCure? InterCure saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 90,200 shares, a decline of 14.6% from the March 15th total of 105,600 shares. Based on an average daily volume of 90,900 shares, the short-interest ratio is currently 1.0 days. Approximately 0.3% of the shares of the stock are sold short. View InterCure's Short Interest. When is InterCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our INCR earnings forecast. How do I buy shares of InterCure? Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INCR) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
